13F HOLDINGS REPORT
Decheng Capital LLC
Quarter ended Q2 2025 · Filed August 13, 2025 · Accession 0001104659-25-077492
Total Value
$396.0M
Positions
25
Other Managers
0
Confidential Omitted
No
Holdings (25)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 6,371,669 | $165.7M | 41.84% |
| 2 | AARDVARK THERAPEUTICS INC | AARD | 3,917,299 | $53.0M | 13.38% |
| 3 | Nuvation Bio Inc. | NUVB | 25,954,439 | $50.6M | 12.78% |
| 4 | Upstream Bio Inc. | UPB | 3,285,293 | $36.1M | 9.11% |
| 5 | NEWAMSTERDAM PHARMA CO NV | NAMSW | 770,000 | $13.9M | 3.52% |
| 6 | BeyondSpring Inc. | BYSI | 4,531,481 | $10.6M | 2.69% |
| 7 | MERUS NV | N5749R100 | 189,098 | $9.9M | 2.51% |
| 8 | KRYSTAL BIOTECH INC | KRYS | 66,000 | $9.1M | 2.29% |
| 9 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 181,600 | $8.6M | 2.16% |
| 10 | REVOLUTION MEDICINES INC(NSM) | RVMDW | 226,000 | $8.3M | 2.10% |
| 11 | Aclaris Therapeutics, Inc. | ACRS | 4,041,736 | $5.7M | 1.45% |
| 12 | Lyell Immunopharma, Inc. | LYEL | 595,466 | $5.3M | 1.33% |
| 13 | ARCELLX INC | ACLX | 547,609 | $4.5M | 1.13% |
| 14 | CRINETICS PHARMACEUTICALS IN | CRNX | 143,000 | $4.1M | 1.04% |
| 15 | Aura Biosciences, Inc. | AURA | 515,555 | $3.2M | 0.82% |
| 16 | Zentalis Pharmaceuticals Inc. | ZNTL | 1,323,327 | $1.5M | 0.39% |
| 17 | Equillium Inc. | EQ | 4,447,308 | $1.4M | 0.35% |
| 18 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 239,510 | $888,582 | 0.22% |
| 19 | Arcus Biosciences, Inc | RCUS | 160,000 | $811,200 | 0.20% |
| 20 | Illumnia, Inc. | ILMN | 7,979 | $761,276 | 0.19% |
| 21 | LEGEND BIOTECH CORP-ADR | LEGN | 20,000 | $709,800 | 0.18% |
| 22 | GRAIL INC | GRAL | 9,684 | $497,951 | 0.13% |
| 23 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $359,491 | 0.09% |
| 24 | REZOLUTE INC | RZLT | 59,900 | $267,154 | 0.07% |
| 25 | Nuvation Bio Inc. | NUVB | 646,057 | $127,347 | 0.03% |